HeartSciences Reminds Its Shareholders to Submit Their Vote at the Upcoming April 30, 2026, Annual Shareholders Meeting
MWN-AI** Summary
HeartSciences Inc. (Nasdaq: HSCS; HSCSW), a healthcare information technology company specializing in electrocardiography (ECG) enhanced by artificial intelligence (AI), has called upon its shareholders to submit their votes for the Annual Meeting scheduled for April 30, 2026, at 10:00 a.m. Eastern Time. This virtual event allows all shareholders of record, as of March 6, 2026, to participate and express their preferences on key company matters.
The company urges all shareholders, regardless of their ownership stakes, to vote using their proxy cards. Voting can be conveniently conducted online through HeartSciences' tabulator, Equiniti, by visiting www.voteproxy.com. To ensure their votes are counted, shareholders must complete their Internet proxy submissions before the deadline of 11:59 p.m. Eastern Time on April 29, 2026.
HeartSciences emphasizes the importance of reviewing its definitive Proxy Statement on Schedule 14A, filed with the U.S. Securities and Exchange Commission on March 17, 2026. This document, along with other materials related to the Annual Meeting, is available to shareholders at no cost on the AST Proxy Portal.
The company is committed to advancing ECG technology through its MyoVista Insights™ Platform, a device-agnostic system designed to enhance clinical efficiency. Its MyoVista wavECG device not only provides standard ECG functionality but also incorporates advanced AI-driven features to support medical decision-making.
In anticipation of the upcoming meeting, HeartSciences reminds shareholders to actively participate in shaping the future of the company, as their votes play a crucial role in guiding its strategic direction. For any assistance regarding the voting process, shareholders can reach out to Advantage Proxy, Inc. through the provided contact details.
MWN-AI** Analysis
As HeartSciences Inc. (NASDAQ: HSCS) gears up for its Annual Shareholders Meeting on April 30, 2026, it is crucial for shareholders to actively participate and cast their votes, particularly amidst a rapidly evolving healthcare technology landscape. HeartSciences is focused on revolutionizing electrocardiography (ECG) through its innovative integration of artificial intelligence, positioning itself as a significant player in the healthcare information technology sector.
For shareholders, voting is not merely a procedural activity; it serves as an opportunity to influence the company's strategic directions and leadership decisions. Given the current industry trends that favor AI-driven healthcare solutions, shareholders should consider how the proposals on the table align with the company's growth trajectory, especially the future direction of its MyoVista Insights™ platform and wavECG device.
Investors should thoroughly review the Proxy Statement filed with the SEC, which outlines crucial information regarding board nominations, compensation plans, and any upcoming corporate initiatives. Key considerations include understanding management’s vision, technology advancements, and competitive positioning against other players in the cardiology space.
Additionally, the potential risks mentioned in the company’s earlier filings highlight the volatility and challenges inherent in technological advancement. Investors must assess these risks against potential rewards, especially as HeartSciences navigates its growth strategy within an increasingly crowded market.
Shareholders are encouraged to vote online through the provided link before the deadline on April 29 to ensure their participation. With its robust pipeline and focus on AI-driven ECG solutions, HeartSciences could potentially offer significant returns for stakeholders who actively engage in the corporate governance process. Thus, it is imperative to not only remain informed but to also be proactive in shaping the future of the company.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Southlake, TX, April 14, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”) a healthcare information technology (“HIT”) company focused on advancing electrocardiography (“ECG” or “EKG”) through the integration of artificial intelligence (“AI”), would like to remind its shareholders to vote ahead of its upcoming Annual Meeting of Shareholders (the “Annual Meeting”) which will be held virtually on Thursday, April 30, 2026, at 10:00 a.m. Eastern Time. All shareholders of record of HeartSciences’ outstanding shares of common stock and Series C preferred stock at the close of business on March 6, 2026, are entitled to participate and vote at the Annual Meeting.
HeartSciences encourages all shareholders vote their proxy card, regardless of how many shares they own.
HeartSciences’ shareholders of record can vote over the Internet, by going to the website of HeartSciences’ tabulator, Equiniti, at www.voteproxy.com. Please have your proxy card in hand when you access the website and follow the instructions to vote your shares. Shareholders of record must submit their Internet proxy before 11:59 p.m., Eastern Time, on April 29, 2026, the day prior to the Annual Meeting, for their proxy to be valid and their vote to count.
For assistance with voting your shares, please contact Advantage Proxy, Inc. toll-free at 1-877-870-8565 or by e-mail at ksmith@advantageproxy.com.
HeartSciences strongly encourages all of its shareholders to read the Company’s definitive Proxy Statement on Schedule 14A, filed with the U.S. Securities and Exchange Commission on March 17, 2026, and other proxy materials relating to the Annual Meeting, which are available free of charge at https://www.astproxyportal.com/ast/27913/ and following the on-screen instructions.
About HeartSciences
HeartSciences is a healthcare information technology (“HIT”) company advancing the use of ECG/EKGs through the integration of artificial intelligence (“AI”). The Company’s MyoVista Insights™ Platform is a device-agnostic, next-generation ECG management system designed to improve clinical efficiency and decision-making. Its MyoVista wavECG device is designed to deliver conventional ECG functionality while supporting on-device AI-enabled solutions.
For more information, please visit: https://www.heartsciences.com. X: @HeartSciences
Safe Harbor Statement
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are made under the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and are relating to the Company's future financial and operating performance. All statements, other than statements of historical facts, included herein are "forward-looking statements" including, among other things, statements about HeartSciences' beliefs and expectations. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company's control. The expectations reflected in these forward-looking statements involve significant assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Potential risks and uncertainties include, but are not limited to, risks discussed in HeartSciences' Annual Report on Form 10-K for the fiscal year ended April 30, 2025, filed with the U.S. Securities and Exchange Commission (the "SEC") on July 24, 2025, HeartSciences’ Quarterly Report on Form 10-Q for the fiscal quarter ended January 31, 2026 filed with the SEC on March 16, 2026, and in HeartSciences' other filings with the SEC at www.sec.gov. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.
Investor Relations:
Integrous Communications
Mark Komonoski, Partner
Phone: 877 255 8483
Email: mkomonoski@integcom.us
Media Contact:
HeartSciences
Gene Gephart
Phone: +1 682 244 2578 Ext. 2024
Email: info@heartsciences.com
FAQ**
How might the outcomes of the upcoming Annual Meeting impact the value and trading activity of the HeartSciences Inc. Warrant HSCSW on the Nasdaq exchange following April 30, 2026?
Given the focus on AI and ECG advancements, how could potential partnerships or innovations by HeartSciences Inc. affect the stock performance of the HeartSciences Inc. Warrant HSCSW post-Annual Meeting?
What are the key risks outlined in HeartSciences' recent filings with the SEC that could affect the viability and trading value of the HeartSciences Inc. Warrant HSCSW investors should consider before the Annual Meeting?
4. What updates or developments can shareholders expect from HeartSciences Inc. HSCS in the upcoming proxy statement regarding future growth and innovation initiatives?
What developments can we expect from HeartSciences Inc. in relation to its MyoVista Insights™ Platform and how might they influence the performance of the HeartSciences Inc. Warrant HSCSW in the near future?
**MWN-AI FAQ is based on asking OpenAI questions about HeartSciences Inc. Warrant (NASDAQ: HSCSW).
NASDAQ: HSCSW
HSCSW Trading
0.0% G/L:
$0.0699 Last:
654 Volume:
$0.0699 Open:
